IDEA Collider: Innovation & Asymmetric Learning in Pharma
door IDEA Pharma, SAI MedPartners
ESMO 2026 Preview: Key studies that could fundamentally change the…
Over deze podcast
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare.
Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking.
Questions We Explore
* What is asymmetric learning, and how does it fuel pharma innovation?
* Why do some organizations outpace others—and what can we learn from them?
* How can we overcome barriers to meaningful progress in healthcare?
* What’s broken in traditional innovation models—and how do we fix it?
🎧 Listen and subscribe on all major platforms.
Afleveringen
De nieuwste 20 van 74 afleveringen
- ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape. · 42 min · Seizoen 3 Aflevering 21In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior…
- AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould. · 41 min · Seizoen 3 Aflevering 20Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic…
- The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II · 36 min · Seizoen 3 Aflevering 19Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank…
- Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy · 49 min · Seizoen 3 Aflevering 18Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of…
- The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access. · 50 min · Seizoen 3 Aflevering 17Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic…
- The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning · 43 min · Seizoen 3 Aflevering 16Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of…
- The Execution Problem: Alex Gray and Jacqueline Poot on Pharma Decision Intelligence. · 1 u 2 min · Seizoen 3 Aflevering 15Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic…
- The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution · 21 min · Seizoen 3 Aflevering 14Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of…
- Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping · 35 min · Seizoen 3 Aflevering 13In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next…
- Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds · 36 min · Seizoen 3 Aflevering 12In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex…
- Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi · 41 min · Seizoen 3 Aflevering 11In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech…
- AI & Competitive Intelligence in Pharma: Smarter Decision-Making with SAI MedPartners · 53 min · Seizoen 3 Aflevering 10In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how…
- Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner · 41 min · Seizoen 3 Aflevering 9In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands…
- Revitalizing Pharma Collaborations: The Reblozyl Case Study · 44 min · Seizoen 3 Aflevering 8In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and…
- Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan · 51 min · Seizoen 3 Aflevering 7In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in…
- Biotech Innovations and AI in Drug Development with Alex Telford: · 54 min · Seizoen 3 Aflevering 6In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio…
- Dr. Christian Rommel on Oncology Innovations and Modern Drug Development at Bayer · 50 min · Seizoen 3 Aflevering 5In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute…
- Bold Science, Bigger Bets: Mathai Mammen on Visionary R&D and Transforming Biopharma · 50 min · Seizoen 3 Aflevering 4In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD…
- Bridging Clinical Practice and Biotech: Paul Peter Tak's Transformative Journey · 50 min · Seizoen 3 Aflevering 3In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading…
- Creating Breakthroughs in Oncology: A Conversation with Susan Galbraith of AstraZeneca · 43 min · Seizoen 3 Aflevering 2In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in…








